Philippe Tessier studied at Laval University, the John Curtin School of Medical Research (Australian National University) and the University of Adelaide, followed by a post-doctoral fellowship at the Imperial Cancer Research Fund (United Kingdom). He has been a researcher at the Centre de recherche du CHU de Québec – Laval University since 1999, and a professor at the Department of Microbiology-Infectiology and Immunology of the Laval University School of Medicine.
Research Projects
Professor Tessier studies the biological activities of the proteins S100A8 and S100A9, two small proteins expressed by neutrophils, monocytes, and activated endothelial and epithelial cells. These proteins are secreted during inflammation and activate the immune response. His research indicates that S100A8 and S100A9 have opposite functions: S100A8 is anti-inflammatory and inhibits myeloid cell differentiation, while S100A9 is pro-inflammatory and induces the differentiation of precursors of neutrophils and monocytes. He studies the roles of these proteins in autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease, in immune responses to solid tumors, and in the differentiation of leukemia cells.
Auto-inflammatory diseases are monogenic orphan diseases (<10,000 cases per syndrome worldwide) usually caused by defects in the genes regulating innate immunity. These diseases are characterized by recurrent, unprovoked inflammation (fever, abdominal pain, rash, arthralgia). High plasma concentrations of S100A8 and S100A9 are often found in patients with auto-inflammatory diseases. In collaboration with Professor Martin Pelletier and Dr. Anne-Laure Chetaille, Prof. Tessier is currently studying the roles of S100A8 and S100A9 in these diseases, to develop a diagnostic test to facilitate the treatment of these patients.
2705, boulevard Laurier
R-0709
Québec, Québec
Canada G1V 4G2
Latest news
- Berrehail, ZohraDoctoral studentCHUL+1 418-525-4444, extension 48288zohra.berrehail@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-0709
Québec, QC
Canada G1V 4G2 - Émond, AudreyEmployeeCHUL+1 418-525-4444, extension 48911audrey.emond@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-0709
Québec, QC
Canada G1V 4G2 - Leblanc, Pier-OlivierMaster studentCHUL+1 418-525-4444, extension 42296pier-olivier.leblanc@crchudequebec.ulaval.ca
2705, boulevard Laurier
T1-49
Québec, QC
Canada G1V 4G2
Immune Cells Release MicroRNA-155 Enriched Extracellular Vesicles That Promote HIV-1 Infection
Journal ArticleCells, 12 (3), 2023.
Acute inflammatory response via neutrophil activation protects against the development of chronic pain
Journal ArticleSci Transl Med, 14 (644), 2022.
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
Journal ArticleLancet Respir Med, 9 (8), 2021.
Velocity Gradient Separation Reveals a New Extracellular Vesicle Population Enriched in miR-155 and Mitochondrial DNA
Journal ArticlePathogens, 10 (5), 2021.
Expression of the myeloid inhibitory receptor CLEC12A correlates with disease activity and cytokines in early rheumatoid arthritis
Journal ArticleSci Rep, 11 (1), 2021.
Deletion of S100a8 and S100a9 Enhances Skin Hyperplasia and Promotes the Th17 Response in Imiquimod-Induced Psoriasis
Journal ArticleJ Immunol, 206 (3), 2021.
The use of leukocytes' secretome to individually target biological therapy in autoimmune arthritis: a case report
Journal ArticleClin Transl Med, 8 (1), 2019.
Enhanced myelopoiesis and aggravated arthritis in S100a8-deficient mice
Journal ArticlePLoS One, 14 (8), 2019.
Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis
Journal ArticleCancer Res, 79 (4), 2019.
Quinoline-3-carboxamides such as tasquinimod are not specific inhibitors of S100A9
Journal ArticleBlood Adv, 2 (10), 2018.
Active projects
- Biology of S100A8 and S100A9 proteins in Human Acute Myeloid Leukemia, from 2019-10-01 to 2024-09-30
- Developing synthetic S100A9-based molecules for differentiation therapy of human acute myeloid leukemia, from 2022-04-01 to 2027-03-31
Recently finished projects
- Surveillance des réponses immunitaires au vaccin contre la COVID-19 chez les personnes vivant avec le VIH-1, from 2021-12-01 to 2022-11-30